Proprietary Products — Operating Income (Loss)
West Pharmaceutical Services Proprietary Products — Operating Income (Loss) decreased by 0.3% to $189.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 44.9%, from $130.60M to $189.20M. Over 2 years (FY 2023 to FY 2025), Proprietary Products — Operating Income (Loss) shows relatively stable performance with a -3.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates improved profitability and operational efficiency, while a decrease signals margin compression or rising costs.
Detailed definition
This is the profit generated from the proprietary products segment after deducting all operating expenses from net sales...
Peer comparison
Standard operating profit metric used across all public companies to assess segment performance.
wst_segment_proprietary_products_operating_income_lossHistorical Data
| Q1 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $193.40M | $170.70M | $194.20M | $181.60M | $163.60M | $126.30M | $131.00M | $158.20M | $162.30M | $130.60M | $161.70M | $175.20M | $189.70M | $189.20M |
| QoQ Change | — | -11.7% | +13.8% | -6.5% | -9.9% | -22.8% | +3.7% | +20.8% | +2.6% | -19.5% | +23.8% | +8.3% | +8.3% | -0.3% |
| YoY Change | — | -11.7% | — | — | — | -26.0% | -32.5% | -12.9% | -0.8% | +3.4% | +23.4% | +10.7% | +16.9% | +44.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's proprietary products — operating income (loss)?
- West Pharmaceutical Services (WST) reported proprietary products — operating income (loss) of $189.20M in Q1 2026.
- How has West Pharmaceutical Services's proprietary products — operating income (loss) changed year-over-year?
- West Pharmaceutical Services's proprietary products — operating income (loss) increased by 44.9% year-over-year, from $130.60M to $189.20M.
- What is the long-term trend for West Pharmaceutical Services's proprietary products — operating income (loss)?
- Over 2 years (2023 to 2025), West Pharmaceutical Services's proprietary products — operating income (loss) has grown at a -3.8% compound annual growth rate (CAGR), from $710.10M to $657.20M.
- What does proprietary products — operating income (loss) mean?
- The profit earned from the proprietary products business after paying all operating costs.